CO5590884A2 - Molecula de insulina que tiene una accion en el tiempo prolongada - Google Patents

Molecula de insulina que tiene una accion en el tiempo prolongada

Info

Publication number
CO5590884A2
CO5590884A2 CO04055341A CO04055341A CO5590884A2 CO 5590884 A2 CO5590884 A2 CO 5590884A2 CO 04055341 A CO04055341 A CO 04055341A CO 04055341 A CO04055341 A CO 04055341A CO 5590884 A2 CO5590884 A2 CO 5590884A2
Authority
CO
Colombia
Prior art keywords
xaa
lys
homoarginine
arg
leu
Prior art date
Application number
CO04055341A
Other languages
English (en)
Inventor
John Michael Beals
Michael Rosario Defelippis
Richard Dennis Marchi
Wayne David Kohn
Micanovic Radmila
Ruth Myers Sharon
Ng Kignman
Zhang Lianshan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5590884A2 publication Critical patent/CO5590884A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1.- Una molécula de insulina que tiene (a) una cadena A de Fórmula I,A-1 A0 A1 A2 A3 A4 A5 A6 A7 A8 Xaa - Xaa - Gly- Ile - Val - Glu - Gln - Cys - Cys - Thr - A9 A10 A11 A12 A13 A14 A15 A16 A17 A18 Ser - Ile - Cys - Ser - Leu - Tyr - Gln - Leu - Glu - Asn - A19 A20 A21 Tyr - Cys - Xaa,en la que la secuencia de aminoácidos de Fórmula I se muestra más adelante en la SEC ID N°. 1, y(b) una cadena B de Fórmula IIB-1 B0 B1 B2 B3 B4 B5 B6 B7 B8 Xaa - Xaa - Phe - Val - Asn - Gln - His- Leu - Cys - Gly- B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 Ser - His - Leu - Val - Glu - Ala - Leu - Tyr - Leu - Val -B19 B20 B21 B22 B23 B24 B25 B26 B27Cys - Gly - Glu - Arg - Gly - Phe - Phe - Tyr - ThrB28 B29 B30 - Xaa - Xaa - Xaa,en la que la secuencia de aminoácidos de Fórmula II se muestra más adelante en la SEC ID N°. 2, donde Xaa en la posición A-1 es Arg, Arg derivatizada, homoarginina, desamino homoarginina, desaminoarginina, Lys Lys derivatizada, desaminolisina, alfa guanidino homoarginina, alfa metil arginina o está ausente;Xaa en la posición A0 es Arg, Arg derivatizada, homoarginina, desamino homoarginina, desaminoarginina, Lys, Lys derivatizada, desaminolisina, alfa guanidino homoarginina o alfa metil arginina;Xaa en la posición A21 es un aminoácido genéticamente codificable;Xaa en la posición B-1 es Arg, Arg derivatizada, homoarginina, desamino homoarginina, desaminoarginina, Lys, Lys derivatizada, desaminolisina, alfa guanidino homoarginina, alfa metil arginina o está ausente;Xaa en la posición B0 es Arg, Arg derivatizada, homoarginina, desamino homoarginina, desaminoarginina, Lys, Lys derivatizada, desaminolisina, alfa guanidino homoarginina, alfa metil arginina o está ausente;Xaa en la posición B28 es Lys o Pro;Xaa en la posición B29 es Lys o Pro;Xaa en la posición B30 es Thr Ala o está ausente;uno de Xaa en la posición B28 o Xaa en la posición B29 es Lys;Xaa en la posición B28 y Xaa en la posición B29 no son ambos Lys; y el grupo e-amino de Lys en la posición B28 o B29 está unido covalentemente al grupo a-carboxilo de un aminoácido cargado positivamente para formar un derivado Lys-Ne -aminoácido.
CO04055341A 2001-12-20 2004-06-11 Molecula de insulina que tiene una accion en el tiempo prolongada CO5590884A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34431001P 2001-12-20 2001-12-20
US41460402P 2002-09-27 2002-09-27

Publications (1)

Publication Number Publication Date
CO5590884A2 true CO5590884A2 (es) 2005-12-30

Family

ID=26993857

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04055341A CO5590884A2 (es) 2001-12-20 2004-06-11 Molecula de insulina que tiene una accion en el tiempo prolongada

Country Status (17)

Country Link
US (1) US20050014679A1 (es)
EP (1) EP1545460A4 (es)
JP (1) JP2005519041A (es)
KR (1) KR20040070237A (es)
AU (1) AU2002346490A1 (es)
BR (1) BR0215029A (es)
CA (1) CA2468100A1 (es)
CO (1) CO5590884A2 (es)
CZ (1) CZ2004710A3 (es)
HR (1) HRP20040551A2 (es)
HU (1) HUP0700126A2 (es)
IL (1) IL161848A0 (es)
MX (1) MXPA04006084A (es)
NO (1) NO20042172L (es)
PL (1) PL374949A1 (es)
SK (1) SK2432004A3 (es)
WO (1) WO2003053339A2 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001560A (es) 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
AU2004269196B2 (en) 2003-09-03 2010-03-04 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
PL2918286T3 (pl) * 2004-10-05 2020-06-29 Novo Nordisk A/S Preparat farmaceutyczny zawierający insulinę w postaci krystalicznej, jak również w formie rozpuszczonej
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
EP2049149B1 (en) * 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009022013A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
KR20100111683A (ko) * 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (en) * 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
AU2009276346B2 (en) * 2008-07-31 2014-07-03 Case Western Reserve University Halogen-stabilized insulin
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
AU2013237740B2 (en) * 2008-07-31 2016-06-02 Case Western Reserve University Insulin analogues containing penta-fluora-phenyalanine at position B24
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
CN102300580A (zh) * 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 二肽连接的药剂
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
AU2009335715B2 (en) * 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
JP2012512900A (ja) * 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション インスリン受容体に対して高い活性を示すｙｌ系インスリン様増殖因子
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
PT2464655T (pt) * 2009-08-11 2017-05-25 Biocon Ltd Processos cromatográficos
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
JP5119232B2 (ja) * 2009-11-06 2013-01-16 株式会社マルハニチロ食品 プロタミンの定量法
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
RU2012123642A (ru) 2009-12-11 2014-01-20 Кейз Вестерн Ризев Юнивесити Аналоги инсулина, содержащие хлорированные аминокислоты
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
BR112012033225A2 (pt) 2010-06-24 2017-06-20 Zealand Pharma As análogos do glucagon
CN103119057B (zh) * 2010-06-24 2016-06-15 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
EP2686003A2 (en) * 2011-03-15 2014-01-22 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP6392123B2 (ja) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 糖尿病治療のためのｃｔｐ系インスリンアナローグ
US9198971B2 (en) * 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
CN104168911A (zh) * 2012-01-20 2014-11-26 卡斯西部储备大学 谷氨酸-稳定的胰岛素类似物
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
CN105745222A (zh) 2013-10-17 2016-07-06 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
TWI670281B (zh) 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
FR3013049B1 (fr) * 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
KR102569743B1 (ko) 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
KR20180002062U (ko) 2016-12-28 2018-07-06 유애자 크리스탈이 구비된 조명커버
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019110625A1 (fr) 2017-12-06 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
MX2020005913A (es) 2017-12-07 2020-10-19 Adocia Solución inyectable a ph 7 que comprende al menos una insulina basal que tiene un pi de entre 5.8 y 8.5 y un copoliaminoácido con cargas de carboxilato y radicales hidrofóbicos.
CA3084689A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3084585B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
WO2020115334A1 (fr) 2018-12-07 2020-06-11 Adocia Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
WO2020245470A1 (fr) 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
ZA928916B (en) * 1991-11-26 1994-05-18 Lilly Co Eli Tri-arginine insulins
DE59409816D1 (de) * 1993-04-27 2001-09-13 Hoechst Ag Amorphe monosphärische Formen von Insulinderivaten
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5491269A (en) * 1994-09-15 1996-02-13 Exxon Production Research Company Method for inhibiting hydrate formation
US5491296A (en) * 1994-12-05 1996-02-13 Holden's Foundation Seeds, Inc. Inbred corn line LH176
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
CN1276731A (zh) * 1997-10-24 2000-12-13 伊莱利利公司 不溶性胰岛素组合物
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives

Also Published As

Publication number Publication date
CZ2004710A3 (cs) 2005-02-16
MXPA04006084A (es) 2005-03-31
EP1545460A4 (en) 2005-11-16
BR0215029A (pt) 2005-12-20
AU2002346490A1 (en) 2003-07-09
IL161848A0 (en) 2005-11-20
JP2005519041A (ja) 2005-06-30
HRP20040551A2 (en) 2004-10-31
WO2003053339A3 (en) 2005-04-14
KR20040070237A (ko) 2004-08-06
PL374949A1 (en) 2005-11-14
US20050014679A1 (en) 2005-01-20
HUP0700126A2 (en) 2007-06-28
NO20042172L (no) 2004-09-17
EP1545460A2 (en) 2005-06-29
SK2432004A3 (sk) 2005-04-01
WO2003053339A2 (en) 2003-07-03
CA2468100A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
CO5590884A2 (es) Molecula de insulina que tiene una accion en el tiempo prolongada
JP2005519041A5 (es)
D’Aloisio et al. PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics
JP6387008B2 (ja) インスリンアナローグダイマー
CA2341037C (en) Bioactive peptides
RU2015143472A (ru) Конъюгаты инсулин-инкретин
Takagi et al. Amino acid sequence studies on the α chain of human fibrinogen. Location of four plasmin attack points and a covalent cross-linking site
ECSP056025A (es) Compuestos glp-1 unidos a polietilenglicol
JP2011511753A5 (es)
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
JP2015532283A5 (es)
SE9100799L (sv) Rekombinant derivat av human faktor viii
BRPI0709014A2 (pt) moléculas modifcadas que promovem hematopoise
US10597426B2 (en) Polypeptide compound and preparation method and use thereof
RU2013146690A (ru) Циклические пептиды с антинеопластической и антиангионенной активностью
KR101750364B1 (ko) 생리활성 펩타이드 복합체
EA201100459A1 (ru) Композиции, включающие интерлейкин-1 и пептиды
RU2014140231A (ru) Антимикробные пептиды
US20230340022A1 (en) Compounds and methods for treating tight junction permeability
CN101072791B (zh) 固相合成中的s-烷基-硫基保护基团
EP3323825A1 (en) Polypeptide compound and preparation method and use thereof
JP2021506815A5 (es)
HUP0301396A2 (hu) Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk
Maeda et al. Design of phenylalanine-containing elastin-derived peptides exhibiting highly potent self-assembling capability
ATE510008T1 (de) Entzündungshemmende peptide

Legal Events

Date Code Title Description
FA Application withdrawn